Unjha Formulations Ltd Downgraded to Strong Sell Amid Mixed Technicals and Flat Financials

Technical Trends Signal Caution

The downgrade was primarily triggered by a shift in the technical grade from sideways to mildly bearish. While the weekly MACD indicator remains bullish, the monthly MACD has turned mildly bearish, signalling a divergence in momentum across timeframes. The weekly Relative Strength Index (RSI) is bearish, indicating weakening short-term price strength, although the monthly RSI shows no clear signal.

Bollinger Bands on both weekly and monthly charts suggest mild bullishness, but this is tempered by daily moving averages that have turned mildly bearish. The KST (Know Sure Thing) indicator presents a mixed picture with weekly readings bullish but monthly readings bearish. Dow Theory analysis reveals no definitive trend on either weekly or monthly scales, adding to the uncertainty.

Overall, these mixed technical signals have contributed to a more cautious stance, with the stock’s price retreating 4.20% on the day to ₹25.10 from a previous close of ₹26.20. The 52-week high stands at ₹29.50, while the low is ₹17.52, indicating a moderate range of volatility over the past year.

Valuation Remains Attractive Despite Downgrade

Contrary to the technical caution, Unjha Formulations’ valuation grade has improved from very attractive to attractive. The company trades at a price-to-earnings (PE) ratio of 23.43, which is reasonable compared to peers such as Hester Biosciences (PE 39) and NGL Fine Chem (PE 43.88). Its price-to-book value stands at 2.93, reflecting a moderate premium over book value but still within an attractive range for investors seeking value.

Enterprise value to EBIT and EBITDA ratios are both at 9.61, indicating a fair valuation relative to earnings before interest and taxes and depreciation. The PEG ratio is exceptionally low at 0.05, signalling that the stock’s price growth is not overextended relative to earnings growth. Return on capital employed (ROCE) is robust at 40.91%, while return on equity (ROE) is a respectable 12.50%, underscoring efficient capital utilisation.

These valuation metrics suggest that despite the downgrade, the stock remains attractively priced relative to its earnings and growth prospects, especially when compared with other pharmaceutical companies in the sector.

Financial Trend: Flat Quarterly Performance and Weak Debt Servicing

Financially, Unjha Formulations has reported flat performance in the first quarter of fiscal year 2026-27, which has contributed to the cautious outlook. The company’s operating profit growth has been modest, with a compound annual growth rate (CAGR) of 6.19% over the past five years, indicating limited expansion in core profitability.

More concerning is the company’s weak ability to service debt, with an average EBIT to interest ratio of just 0.43. This low coverage ratio suggests that earnings before interest and taxes are insufficient to comfortably meet interest obligations, raising questions about financial stability in a rising interest rate environment.

Despite these challenges, the company has delivered market-beating returns over the long term. It has generated a 4.02% return over the past year, outperforming the BSE Sensex which declined by 2.64% in the same period. Over three and five years, returns have been even more impressive at 94.42% and 129.85% respectively, far exceeding the Sensex’s 19.57% and 44.20% gains.

Quality Assessment: Micro-Cap Status and Shareholder Composition

Unjha Formulations is classified as a micro-cap company, which inherently carries higher risk due to lower liquidity and market capitalisation. The majority of its shares are held by non-institutional investors, which can lead to greater volatility and less predictable trading patterns.

The company’s Mojo Score stands at 28.0, with a Mojo Grade of Strong Sell, downgraded from Sell on 5 August 2026. This score reflects the combined assessment of quality, valuation, financial trends, and technicals, signalling a cautious stance for investors.

Comparative Performance and Market Context

Unjha Formulations’ stock price has experienced notable volatility in the short term, with a one-week return of -8.73% contrasting sharply with the Sensex’s 1.19% gain. However, the one-month return of 35.31% significantly outpaces the Sensex’s 1.05%, reflecting episodic rallies. Year-to-date, the stock has marginally outperformed the benchmark with a 0.4% gain versus a 7.79% decline in the Sensex.

Longer-term performance remains a bright spot, with the stock delivering nearly double the Sensex’s returns over three and five years. This suggests that while short-term technical and financial concerns have weighed on sentiment, the company’s underlying business has demonstrated resilience and growth potential.

Investors should weigh these mixed signals carefully. The attractive valuation and strong long-term returns are offset by recent flat financial results, weak debt servicing capacity, and a shift towards bearish technical indicators. The downgrade to Strong Sell reflects this nuanced outlook, advising caution in portfolio allocation.

Conclusion: A Complex Outlook Demands Vigilance

Unjha Formulations Ltd’s recent downgrade to Strong Sell by MarketsMOJO encapsulates a multifaceted assessment of the company’s prospects. While valuation metrics remain attractive and long-term returns impressive, the technical indicators have shifted towards caution, and financial trends reveal vulnerabilities in profitability growth and debt servicing.

For investors, this means that despite the stock’s micro-cap status and potential for upside, the risks have increased. The downgrade serves as a reminder to monitor technical signals closely and consider alternative investments that may offer more stable growth trajectories and financial health.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →